Leproust Emily M. sold 4,573 shares of Twist Bioscience Corp at $135.40 for −$619k on Nov 3, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Executive Officer
Chief Executive Officer
Filed Nov 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$619,193.35Shares × reported price
Shares traded
4,573Common Stock
Price per share
$135.40Reported price. Read footnotes for ranges.
% of reported position traded
0.81%This security and ownership context
Holdings after
558,187Direct
Trade date
Nov 3, 2026Sell
Filed
Nov 5, 2026, 4:05 PM ET2-day reporting delay
Accession
0001214659-26-013781Code S · Transaction 393362
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 562,760 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

TWST price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TWST · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +56%1w ago +33%1d ago +7%
Returns since7d +1.6%30d90d180d1y

Footnotes in full

F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. F3: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.